JACC. Case reports · 2026
Trabectedin-Associated Myocardial Infarction With Nonobstructive Coronary Arteries.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dasari Srikiran, Aviles Eduardo Alfredo, Patel Brijesh
Аннотация
BACKGROUND: Trabectedin is a marine-derived alkylating agent used to treat soft tissue sarcomas.
CASE SUMMARY: We present a case of myocardial infarction with nonobstructive coronary arteries (MINOCA) in a 58-year-old man with no prior cardiac history who was receiving trabectedin for metastatic liposarcoma. Initial work-up revealed elevated high-sensitivity troponin, unremarkable electrocardiogram and echocardiogram, and mild nonobstructive coronary disease on coronary angiography. The patient's chest discomfort recurred days after another chemotherapy cycle, and it was hypothesized that coronary vasospasm produced his symptoms. Prophylactic amlodipine and isosorbide mononitrate were administered around subsequent cycles, with complete resolution of symptoms.
DISCUSSION: Recurrent episodes of acute coronary syndrome after trabectedin infusions that resolved with vasodilator pretreatment supported trabectedin-induced coronary vasospasm as the mechanism of MINOCA in this patient. This is to our knowledge the first reported such case with trabectedin.
TAKE-HOME MESSAGE: Patients who develop trabectedin-associated MINOCA may benefit from pretreatment with anti-vasospastic antianginals to allow for safe continuation of therapy.
CASE SUMMARY: We present a case of myocardial infarction with nonobstructive coronary arteries (MINOCA) in a 58-year-old man with no prior cardiac history who was receiving trabectedin for metastatic liposarcoma. Initial work-up revealed elevated high-sensitivity troponin, unremarkable electrocardiogram and echocardiogram, and mild nonobstructive coronary disease on coronary angiography. The patient's chest discomfort recurred days after another chemotherapy cycle, and it was hypothesized that coronary vasospasm produced his symptoms. Prophylactic amlodipine and isosorbide mononitrate were administered around subsequent cycles, with complete resolution of symptoms.
DISCUSSION: Recurrent episodes of acute coronary syndrome after trabectedin infusions that resolved with vasodilator pretreatment supported trabectedin-induced coronary vasospasm as the mechanism of MINOCA in this patient. This is to our knowledge the first reported such case with trabectedin.
TAKE-HOME MESSAGE: Patients who develop trabectedin-associated MINOCA may benefit from pretreatment with anti-vasospastic antianginals to allow for safe continuation of therapy.